Marianne Ifversen

Prof. Marianne Ifversen

Rigshospitalet, Copenhagen, Hovedstaden, Denmark

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
MIMarianne Ifversen
Marianne Ifversen
RMRoland Meisel
Roland Meisel
PSPetr Sedlacek
Petr Sedlacek
KKKrzysztof Kalwak
Krzysztof Kalwak
LSLuisa Sisinni
Luisa Sisinni
PBPeter Bader
Peter Bader
Specific protocols define eligibility, conditioning, donor selection, graft composition and prophylaxis of graft vs. host disease for children and young adults undergoing hematopoietic stem cell transplant (HSCT). However, international protocols rarely, if ever, detail supportive care, including pharmaceutical infection prophylaxis, physical protection with face masks and cohort isolation or food restrictions. Supportive care suffers from a lack of scientific evidence and implementation of practices in the transplant centers brings extensive restrictions to the child's and family's daily life after HSCT. Therefore, the Board of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) held a series of dedicated workshops since 2017 with the aim of initiating the production of a set of minimal recommendations. The present paper describes the consensus reached within the field of infection prophylaxis.

1 March 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
PPPeter L. Pontoppidan
Peter L. Pontoppidan
KJKarina Jordan
Karina Jordan
ACAnting Liu Carlsen
Anting Liu Carlsen
HUHilde Hylland Uhlving
Hilde Hylland Uhlving
KKKatrine Kielsen
Katrine Kielsen
Klaus MüllerKlaus Müller
Klaus Müller

21 September 2018 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
O(On Behalf Of The Nordic Society Of Pediatric Hematology And Oncology (Nopho)
On Behalf Of The Nordic Society Of Pediatric Hematology And Oncology (Nopho)
MWMari Wilhelmsson
Mari Wilhelmsson
HGHeidi Glosli
Heidi Glosli
MIMarianne Ifversen
Marianne Ifversen
JAJonas Abrahamsson
Jonas Abrahamsson
HHHenrik Hasle
Henrik Hasle
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improves event-free survival in acute myeloid leukemia (AML); however, the burden of late effects may be increased. We compared health-related outcomes in childhood AML survivors treated according to the NOPHO-AML protocols either with or without allo-HSCT at age < 21 years. Out of the 147 eligible AML survivors treated with allo-HSCT, 95 (65%) and 53 (75%) of their eligible siblings completed a questionnaire. Their data were compared to corresponding data collected previously from NOPHO-AML survivors treated with chemotherapy only (CT) (n = 101). The median follow-up was 12 (range 2–28) years after allo-HSCT and 47% had received total body irradiation (TBI)-based conditioning. Allo-HSCT survivors reported significantly more physical health limitations (39% vs 7%, p < 0.005), medications for cardiovascular disease (10% vs 1%, p < 0.05) and use of analgesics (32% vs 11%, p < 0.01) than CT survivors. Health problems prevented 16% of the allo-HSCT survivors from attending school or managing a job vs. 3% among CT survivors (p < 0.05). Among 73 allo-HSCT survivors (age ≥ 15 years), seven females reported natural pregnancies and three males reported unassisted conceptions in partners. Survivors of childhood AML treated with allo-HSCT experienced more physical health limitations and used more medications than the survivors treated with chemotherapy only.

23 December 2014 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
KKKatrine Kielsen
Katrine Kielsen
KJKarina K. Jordan
Karina K. Jordan
HUHilde H. Uhlving
Hilde H. Uhlving
PPPeter L. Pontoppidan
Peter L. Pontoppidan
ZSZaiba Shamim
Zaiba Shamim
Klaus MüllerKlaus Müller
Klaus Müller
Infections and acute graft‐versus‐host disease (aGVHD) are major causes of treatment‐related mortality and morbidity following allogeneic haematopoietic stem cell transplantation (HSCT). Both complications depend on reconstitution of the T‐lymphocyte population based on donor T cells. Although it is well established that Interleukin‐7 (IL‐7) is a cytokine essential for de novo T cell development in the thymus and homoeostatic peripheral expansion of T cells, associations between circulating levels of IL‐7 and T cell reconstitution following HSCT have not been investigated previously. We prospectively measured IL‐7 levels in 81 patients undergoing myeloablative HSCT with either sibling donor or an unrelated donor. Plasma IL‐7 levels peaked at day +7 post‐transplant (1.3–82.4 pg/ml), at the time of maximal lymphopaenia. In multivariate analysis, peak levels of IL‐7 were significantly higher in patients treated with anti‐thymocyte globulin (ATG) compared with those not treated with ATG (P = 0.0079). IL‐7 levels at day +7 were negatively associated with T cell counts at day +30 to +60 (at day +60: CD3+: β = −10.6 × 106 cells/l, P = 0.0030; CD8+: β = −8.4 × 106 cells/l, P = 0.061; CD4+: β = −2.1 × 106 cells/l, P = 0.062) in multivariate analyses. In adults, high IL‐7 levels were associated with increased risk of grade II‐IV aGVHD (OR = 5.4, P = 0.036) and reduced overall survival (P = 0.046). The present data indicate that high plasma levels of IL‐7 in the early post‐transplant period are predictive for slow T cell reconstitution, increased risk of aGVHD and increased mortality following HSCT.

3 July 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
AKAnne Mols Krarup
Anne Mols Krarup
HUHilde Hylland Uhlving
Hilde Hylland Uhlving
RSRudi Steffensen
Rudi Steffensen
KKKatrine Kielsen
Katrine Kielsen
CHCarsten Heilmann
Carsten Heilmann
KMKlaus Mueller
Klaus Mueller

12 January 2021
Verified
Journal Article
Closed access
SBShahrzad Bakhtiar
Shahrzad Bakhtiar
ESEmilia Salzmann-Manrique
Emilia Salzmann-Manrique
HBHenric-Jan Blok
Henric-Jan Blok
DEDirk-Jan Eikema
Dirk-Jan Eikema
SHSheree Hazelaar
Sheree Hazelaar
ALArjan Lankester
Arjan Lankester
Type I and III leukocyte adhesion deficiencies (LADs) are primary immunodeficiency disorders resulting in early death due to infections and additional bleeding tendency in LAD-III. The curative treatment of LAD-I and LAD-III is allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this retrospective multicenter study, data were collected using the European Society for Blood and Marrow Transplantation registry; we analyzed data from 84 LAD patients from 33 centers, all receiving an allo-HSCT from 2007 to 2017. The 3-year overall survival estimate (95% confidence interval [CI]) was 83% (74-92) for the entire cohort: 84% (75-94) and 75% (50-100) for LAD-I and LAD-III, respectively. We observed cumulative incidences (95% CI) of graft failure (GF) at 3 years of 17% (9%-26%) and grade II to IV acute graft-versus-host disease (aGVHD) at 100 days of 24% (15%-34%). The estimate (95% CI) at 3 years for GF- and GVHD-II to IV-free survival as event-free survival (EFS) was 56% (46-69) for the entire cohort; 58% (46-72) and 56% (23-88) for LAD-I and LAD-III, respectively. Grade II to IV acute GVHD was a relevant risk factor for death (hazard ratio 3.6; 95% CI 1.4-9.1; P = .006). Patients' age at transplant >= 13 months, transplantation from a nonsibling donor, and any serological cytomegalovirus mismatch in donor-recipient pairs were significantly associated with severe acute GVHD and inferior EFS. The choice of busulfan- or treosulfan-based conditioning, type of GVHD prophylaxis, and serotherapy did not impact overall survival, EFS, or aGVHD. An intrinsic inflammatory component of LAD may contribute to inflammatory complications during allo-HSCT, thus providing the rationale for considering anti-inflammatory therapy pretreatment.